Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.372 EUR | +5.90% |
|
-2.26% | -28.56% |
01:00pm | New semester, new state of mind | ![]() |
12:05pm | Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.56% | 475M | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.17% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva : Jefferies Initiates Valneva SE at Buy With $36 Price Target